EP. 8: RRMM: Adopting Anti-BCMA Therapy into Practice
March 17th 2021
Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.